J&J's Janssen: Credence Trial of Invokana Being Stopped Early for Positive Efficacy Findings

The Janssen Pharmaceutical Companies of Johnson & Johnson said Monday they were stopping the Phase 3 Credence clinical trial of Invokana early based on the achievement of pre-specified efficacy criteria.

Dr. Vlado Perkovic, co-chair of the company's Credence Steering Committee, said "We have accepted the advice of the Independent Data Monitoring Committee to stop the CREDENCE trial early due to demonstration of efficacy, and look forward to sharing the findings as soon as possible."

The Credence, or Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation clinical trial, was evaluating "the efficacy and safety of Invokana (canagliflozin) versus placebo when used in addition to standard of care for patients with chronic kidney disease and type 2 diabetes," the company said.

"Invokana has the potential to be the first new therapy in more than 15 years for slowing the progression of chronic kidney disease in patients with type 2 diabetes," the company stated.

Company website:

https://www.janssen.com/us

--By Stephen Nakrosis; [e-mail]

(END) Dow Jones Newswires

July 16, 2018 17:15 ET (21:15 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.